“Generalized Pustular Psoriasis (GPP) Control is Limited on Traditional Small-molecule Therapy as Measured by the GPP Physician Global Assessment (GPPGA) and Dermatology Life Quality Index (DLQI): Baseline Data from the EFFISAYIL® 2 Trial”, J of Skin, vol. 9, no. 2, p. s540, Mar. 2025, doi: 10.25251/skin.10.supp.540.